FT576 in Subjects With Multiple Myeloma

General Information

Summary This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Clinical trials phase Phase 1
Start date (estimated) 2021-11-24
End date (estimated) 2040-02-29
Clinical feature
Label multiple myeloma
Link http://purl.obolibrary.org/obo/DOID_9538
Description A myeloid neoplasm that is located_in the plasma cells in bone marrow.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT05182073
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05182073
Other study identifiers
Name FT576-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT05182073
Regulatory body approval
Name Food and Drug Administration (FDA)
United States
Public contact
Email FateTrialDisclosure@fatetherapeutics.com
Public email FateTrialDisclosure@fatetherapeutics.comFateTrialDisclosure@fatetherapeutics.com
First name Fate Trial Disclosure
Last name Fate Trial Disclosure
Phone +1 866-875-1800
United States
Sponsors Fate Therapeutics


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 168